Fougera, a division of Nycomed US Inc, announced the FDA has approved its Clotrimazole Cream USP 1 per cent. 

The generic formulation compares to Taro's Referenced Listed Drug (RLD) and is available in three sizes: 15g tubes (NDC # 0168-0133-15), 30g tubes (NDC # 0168-0133-30) and 45g tubes (NDC # 0168-0133-46).

"The approval of Clotrimazole Cream is another illustration of Fougera's robust product pipeline," stated David Klaum, senior vice president and general manager Fougera "With each product approval, Fougera reaffirms its commitment to providing safe, effective and affordable options to health care providers and their patients."

Founded in 1849, Fougera is a division of Nycomed US, Inc and is the leading manufacturer and distributor of a wide range of topical products. Nycomed US, Inc is a subsidiary of Nycomed. In addition to Fougera, Nycomed US, Inc operates two additional divisions of specialty pharmaceuticals.